= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Barré

MSACL 2018 EU Abstract

Topic: Tissue Imaging

Podium Presentation in the Ether on Wednesday at 9:40 (Chair: Vladimir Frankevich)

MALDI Imaging Through Laser-Induced Post-Ionization Pushes the Boundaries of Pharmaceutical Development Studies

Florian Barré (Presenter)
M4I, Maastricht University

Presenter Bio(s): I obtained a bachelor specialized in cell biology and physiology that I got at Lille 1 University in France. I graduated with honors in 2015 with a Proteomics master that I also got at Lille 1 University with Isabelle Fournier and Michel Salzet as directors of the master. During my master, I went to Copenhagen at BRIC institute for 6 months for my first year internship where my project was to create luminescent and fluorescent cancer cell lines in Lund Anders’s laboratory. For my second year of master I went to Uppsala University, at Per Andrén’s laboratory for a project concerning the quantitation of a drug in the brain by MSI coupled to LC-MS for 6 months as well.
Afterwards, Ron Heeren and Berta Cillero-Pastor offered me the opportunity to work on cartilage regeneration within a Marie Curie consortium. During PhD, I tried to be involved in the MSI community. For this reason, I was p

Authors: Florian P.Y. Barré(1), Martin R.L. Paine(1), Bryn Flinders(1), Rima Ait-Belkacem(2), João P. Garcia(4), Laura B. Creemers(4), Jonathan Stauber(2), Rob Vreeken(1,3), Berta Cillero-Pastor(1), Shane R. Ellis(1), Ron M.A. Heeren(1)
(1)The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands (2)ImaBiotech, MS Imaging Dept., Loos, France (3)Discovery Sciences, Janssen Research & Development, Beerse, Belgium (4)University Medical Centre (UMC) Utrecht, Orthopedics Department, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

Abstract

Drug imaging is one of the major mass spectrometry imaging (MSI) applications. However, drug development through MSI has some limitations. Indeed, some compounds are not easily detectable due to poor ionization efficiency and ion suppression effects. In this work, we used post-ionization matrix assisted laser desorption/ionization (MALDI-2) to overcome these problems and we are showing that 80% of the drugs we tested directly benefit from ionization enhancement. We are now able to detect pharmaceuticals that are non-detectable by conventional MALDI pushing the boundaries of MSI for drug studies.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no